Taken together, these results indicate that PPARγ agonist treatment improved several metabolic disorders independently of adipose tissue function in aKO mice, suggesting that HMGCR-mediated lipodystrophy was minimally associated with the deficiency of MVA-derivative PPARγ ligands. The gene discussed is HMGCR; the disease is Other metabolic disease.